Par Launches Cortisporin-TC Otic Suspension

Par Launches Cortisporin-TC Otic Suspension
Par Launches Cortisporin-TC Otic Suspension

Par announced the launch of Cortisporin-TC (colistin sulfate, neomycin sulfate, thonzonium bromide, hydrocortisone acetate) Otic Suspension for the treatment of otitis externa caused by susceptible organisms and for the treatment of mastoidectomy and fenestration cavities caused by susceptible organisms.

Cortisporin-TC Otic Suspension combines the antibiotics colistin sulfate and neomycin sulfate; the steroid hydrocortisone acetate, and the surfactant thonzonium bromide. Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a corticosteroid thought to act by regulating the rate of protein synthesis; it controls inflammation, edema, pruritus and other dermal reactions. Thonzonium bromide promotes tissue contact by dispersion and penetration of the cellular exudate.

RELATED: Can a Drug Used to Treat Stroke Be Effective for Otitis Media?

Cortisporin-TC Otic Suspension was acquired by Par from JHP Pharmaceuticals in the first quarter of 2014. It is available in a 10mL bottle with a sterilized dropper-cap assembly for use.

For more information call (800) 828-9393 or visit ParPharm.com.

Loading links....